News

Protalix has initiated home care treatment program for patients enrolled in the phase-III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD). The phase-III extension trial is a follow-on

AstraZeneca and Bristol-Myers’ marketing authorisation application for Onglyza (saxagliptin) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), for Onglyza. It is

A subsidiary of Ligand has entered into an exclusive license agreement with ParinGenix. Under the agreement, ParinGenix was granted exclusive license rights to three issued US patents relating

The test will be developed by using Chembio’s patented Dual Path Platform (DPP) technology together with proprietary reagents developed by Cornell University and the Oswaldo Cruz Foundation at

Allscripts has announced that Diagnostic Center of Medicine (DCOM) has selected Allscripts Electronic Health Record (EHR) and Practice Management (PM) for its physicians in three locations. DCOM is

Pintek is an industry veteran with deep and broad experience in the life science industry. He joins Luminex from Roche, where he has held several positions of increasing

Oculus Innovative Sciences (Oculus) has confirmed the effectiveness of Microcyn Technology at inactivating the H1NI Swine Influenza A. A virucidal time-kill suspension test conducted by BioScience Laboratories showed

Watson has announced that its subsidiary, Watson Laboratories, has received FDA approval for its Abbreviated New Drug Application (ANDA). The approval is meant for its levonorgestrel tablets, 0.75

Living Cell Technologies (LCT) has announced that New Zealand Ministery of Health has authorized LCT’ New Zealand phase I/IIa clinical trial of Diabecell, for insulin dependent diabetes. The